Cargando…

Treatment Outcomes After Offering Same-Day Initiation of Human Immunodeficiency Virus Treatment—How to Interpret Discrepancies Between Different Studies

The World Health Organization recommends same-day initiation of antiretroviral therapy (ART) for all persons diagnosed with HIV and ready to start treatment. Evidence, mainly from randomized trials, indicates offering same-day ART increases engagement in care and viral suppression during the first y...

Descripción completa

Detalles Bibliográficos
Autores principales: Labhardt, Niklaus Daniel, Brown, Jennifer Anne, Sass, Nikita, Ford, Nathan, Rosen, Sydney
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573746/
https://www.ncbi.nlm.nih.gov/pubmed/37229594
http://dx.doi.org/10.1093/cid/ciad317
_version_ 1785120533440888832
author Labhardt, Niklaus Daniel
Brown, Jennifer Anne
Sass, Nikita
Ford, Nathan
Rosen, Sydney
author_facet Labhardt, Niklaus Daniel
Brown, Jennifer Anne
Sass, Nikita
Ford, Nathan
Rosen, Sydney
author_sort Labhardt, Niklaus Daniel
collection PubMed
description The World Health Organization recommends same-day initiation of antiretroviral therapy (ART) for all persons diagnosed with HIV and ready to start treatment. Evidence, mainly from randomized trials, indicates offering same-day ART increases engagement in care and viral suppression during the first year. In contrast, most observational studies using routine data find same-day ART to be associated with lower engagement in care. We argue that this discrepancy is mainly driven by different time points of enrollment, leading to different denominators. While randomized trials enroll individuals when tested positive, most observational studies start at the time point when ART is initiated. Thus, most observational studies omit those who are lost between diagnosis and treatment, thereby introducing a selection bias in the group with delayed ART. This viewpoint article summarizes the available evidence and argues that the benefits of same-day ART outweigh a potential higher risk of attrition from care after ART initiation.
format Online
Article
Text
id pubmed-10573746
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105737462023-10-14 Treatment Outcomes After Offering Same-Day Initiation of Human Immunodeficiency Virus Treatment—How to Interpret Discrepancies Between Different Studies Labhardt, Niklaus Daniel Brown, Jennifer Anne Sass, Nikita Ford, Nathan Rosen, Sydney Clin Infect Dis Viewpoints Article The World Health Organization recommends same-day initiation of antiretroviral therapy (ART) for all persons diagnosed with HIV and ready to start treatment. Evidence, mainly from randomized trials, indicates offering same-day ART increases engagement in care and viral suppression during the first year. In contrast, most observational studies using routine data find same-day ART to be associated with lower engagement in care. We argue that this discrepancy is mainly driven by different time points of enrollment, leading to different denominators. While randomized trials enroll individuals when tested positive, most observational studies start at the time point when ART is initiated. Thus, most observational studies omit those who are lost between diagnosis and treatment, thereby introducing a selection bias in the group with delayed ART. This viewpoint article summarizes the available evidence and argues that the benefits of same-day ART outweigh a potential higher risk of attrition from care after ART initiation. Oxford University Press 2023-05-25 /pmc/articles/PMC10573746/ /pubmed/37229594 http://dx.doi.org/10.1093/cid/ciad317 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Viewpoints Article
Labhardt, Niklaus Daniel
Brown, Jennifer Anne
Sass, Nikita
Ford, Nathan
Rosen, Sydney
Treatment Outcomes After Offering Same-Day Initiation of Human Immunodeficiency Virus Treatment—How to Interpret Discrepancies Between Different Studies
title Treatment Outcomes After Offering Same-Day Initiation of Human Immunodeficiency Virus Treatment—How to Interpret Discrepancies Between Different Studies
title_full Treatment Outcomes After Offering Same-Day Initiation of Human Immunodeficiency Virus Treatment—How to Interpret Discrepancies Between Different Studies
title_fullStr Treatment Outcomes After Offering Same-Day Initiation of Human Immunodeficiency Virus Treatment—How to Interpret Discrepancies Between Different Studies
title_full_unstemmed Treatment Outcomes After Offering Same-Day Initiation of Human Immunodeficiency Virus Treatment—How to Interpret Discrepancies Between Different Studies
title_short Treatment Outcomes After Offering Same-Day Initiation of Human Immunodeficiency Virus Treatment—How to Interpret Discrepancies Between Different Studies
title_sort treatment outcomes after offering same-day initiation of human immunodeficiency virus treatment—how to interpret discrepancies between different studies
topic Viewpoints Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573746/
https://www.ncbi.nlm.nih.gov/pubmed/37229594
http://dx.doi.org/10.1093/cid/ciad317
work_keys_str_mv AT labhardtniklausdaniel treatmentoutcomesafterofferingsamedayinitiationofhumanimmunodeficiencyvirustreatmenthowtointerpretdiscrepanciesbetweendifferentstudies
AT brownjenniferanne treatmentoutcomesafterofferingsamedayinitiationofhumanimmunodeficiencyvirustreatmenthowtointerpretdiscrepanciesbetweendifferentstudies
AT sassnikita treatmentoutcomesafterofferingsamedayinitiationofhumanimmunodeficiencyvirustreatmenthowtointerpretdiscrepanciesbetweendifferentstudies
AT fordnathan treatmentoutcomesafterofferingsamedayinitiationofhumanimmunodeficiencyvirustreatmenthowtointerpretdiscrepanciesbetweendifferentstudies
AT rosensydney treatmentoutcomesafterofferingsamedayinitiationofhumanimmunodeficiencyvirustreatmenthowtointerpretdiscrepanciesbetweendifferentstudies